CLS presents its new strategic direction in a Business Update Event on June 12
Lund, Sverige – Clinical Laserthermia Systems AB (publ) (CLS) recently announced a new strategic focus based on the opportunities within the neurosurgery segment. CLS welcomes investors, media, and the public to virtually attend a Live Business Update Event on June 12, 2024, at 9.30 CEST.
During the event, the company will give an update on the recently announced strategic focus on neurosurgery. Special attention will be given to the ongoing commercial launch of the ClearPoint Prism product offering in the US.
Following the completion of the presentation, viewers will have the opportunity to ask questions through the webcast video chat.
The presentation will be held in Swedish by Dan Mogren, CEO, and Hans von Celsing, Chairman of CLS.
Link to attend the Business Update Event: Business Update: Clinical Laserthermia Systems - Redeye
Link to the Press Release about new strategic direction: CLS (clinicallaser.se)
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se